High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases

被引:5
|
作者
Casey, Dana L. [1 ]
Pitter, Kenneth L. [1 ]
Imber, Brandon S. [1 ]
Lin, Andrew [2 ]
Chan, Timothy A. [1 ]
Beal, Kathryn [1 ]
Yamada, Yoshiya [1 ]
Feldman, Darren R. [3 ]
Yang, T. Jonathan [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Neurooncol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
Non-seminomatous germ cell tumor; Brain metastases; Whole brain radiation therapy; Stereotactic radiosurgery; Dose-response relationship; CANCER; CHEMOTHERAPY; RADIOTHERAPY; MANAGEMENT;
D O I
10.1007/s11060-019-03123-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe presence of brain metastases (BM) in patients with non-seminomatous germ cell tumor (NSGCT) is associated with poor prognosis. While radiation therapy (RT) is an important treatment for patients with NSGCT BM, there is a paucity of data on the optimal regimen. We sought to investigate the impact of RT on clinical outcomes in patients with NSGCT BM.MethodsPatients with NSGCT BM who received RT at our institution from 2002 to 2017 were included. Sixty-three consecutive patients were identified. Clinical factors associated with intracranial control (ICC) and overall survival (OS) were evaluated using cox regression analysis and Kaplan Meier method.ResultsMedian age was 31years and number of BM was three. Fifteen patients presented with BM at diagnosis, while 48 developed BM at a median time of 8.4months from diagnosis. At a median follow-up of 3.6years, ICC and OS were 39.7% and 30.1%. On multivariate analysis, ICC (hazard ratio [HR]=0.93, p=0.03) and OS (HR=0.93, p=0.005) were both significantly associated with biologically effective dose (BED) of RT. The 4-year OS of patients who received BED<39Gy, 39Gy, 40-50Gy, and 50Gy were 0%, 14.7%, 34.1%, and 70.0%, respectively. Patients who achieved ICC after RT were able to achieve long-term survival (4-year OS 68.1% vs. 0%, p<0.0001).ConclusionsOur data supports that a higher BED is required for durable ICC, and that ICC is needed for patients with NSGCT to achieve long-term survival. Prospective studies evaluating radiation dose-escalation for the treatment of NSGCT BM should be considered.
引用
收藏
页码:523 / 528
页数:6
相关论文
共 50 条
  • [41] Long-term survival in an adult metastatic renal peripheral primitive neuroectodermal tumor (PPNET) with multimodality treatment including high-dose chemotherapy
    Fontaine, C
    Schots, R
    Braeckman, J
    Goossens, A
    Soete, G
    DeGreve, J
    ANNALS OF ONCOLOGY, 1997, 8 (07) : 691 - 694
  • [42] High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
    Abrey, LE
    Childs, BH
    Paleologos, N
    Kaminer, L
    Rosenfeld, S
    Salzman, D
    Finlay, JL
    Gardner, S
    Peterson, K
    Hu, W
    Swinnen, L
    Bayer, R
    Forsyth, P
    Stewart, D
    Smith, AM
    Macdonald, DR
    Weaver, S
    Ramsay, DA
    Nimer, SD
    DeAngelis, LM
    Cairncross, JG
    NEURO-ONCOLOGY, 2006, 8 (02) : 183 - 188
  • [43] Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer
    Zelefsky, Michael J.
    Chan, Heather
    Hunt, Margie
    Yamada, Yoshiya
    Shippy, Alison M.
    Amols, Howard
    JOURNAL OF UROLOGY, 2006, 176 (04) : 1415 - 1419
  • [44] Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract A case report
    Werthmann, Paul G.
    Hintze, Alexander
    Kienle, Gunver S.
    MEDICINE, 2017, 96 (46)
  • [45] Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
    Bersvendsen, Hanne Skjerven
    Haugnes, Hege Sagstuen
    Dahl, Alv A.
    Fagerli, Unn-Merete
    Fluge, Oystein
    Holte, Harald
    Seland, Mette
    Wilsgaard, Tom
    Smeland, Knut Bjoro
    Kiserud, Cecilie Essholt
    BONE MARROW TRANSPLANTATION, 2020, 55 (05) : 891 - 905
  • [46] Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases
    Shriyan, Bharati
    Patil, Deepali
    Gurjar, Murari
    Nookala, Manjunath
    Patil, Anand
    Kannan, Sadhana
    Patil, Vijay
    Joshi, Amit
    Noronha, Vanita
    Prabhash, Kumar
    Gota, Vikram
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1427 - 1436
  • [47] Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
    Stenehjem, Jo S.
    Smeland, Knut B.
    Murbraech, Klaus
    Holte, Harald
    Kvaloy, Stein Olav
    Wethal, Torgeir
    Kiserud, Cecilie E.
    Samersaw-Lund, May Brit
    ACTA ONCOLOGICA, 2018, 57 (06) : 773 - 781
  • [48] Postoperative long-term survival of non-small cell lung cancer patients with skip-N2 metastases
    Schlachtenberger, Georg
    Doerr, Fabian
    Menghesha, Hruy
    Heldwein, Matthias B.
    Hagmeyer, Lars
    Michel, Maximilian
    Schaefer, Stephan C.
    Wahlers, Thorsten
    Hekmat, Khosro
    SURGICAL ONCOLOGY-OXFORD, 2021, 38
  • [49] Long-term Survival of a Patient with Splenic Angiosarcoma after Resection, High-dose Chemotherapy, and Autologous Peripheral Blood Stem Cell Transplantation
    Hara, Takeshi
    Tsurumi, Hisashi
    Kasahara, Senji
    Ogawa, Kengo
    Takada, Jun
    Imai, Kenji
    Takai, Koji
    Kitagawa, Jun-ichi
    Kiyama, Shigeru
    Imai, Naoki
    Oyama, Masami
    Takami, Tsuyoshi
    Moriwaki, Hisataka
    INTERNAL MEDICINE, 2010, 49 (20) : 2253 - 2257
  • [50] SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
    Nagaki, Yushi
    Motoyama, Satoru
    Sato, Yusuke
    Wakita, Akiyuki
    Fujita, Hiromu
    Sasaki, Yoshihiro
    Imai, Kazuhiro
    Minamiya, Yoshihiro
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)